- KetaDASH will begin using precision medicine to improve patient outcomes through its partnership with HaluGen Life Sciences, owned by Entheon Biomedical Corp (ENBI)
- KetaDASH is a subsidiary of Ehave Inc
- KetaDASH will become one of the first psychedelic companies to use precision medicine to test patients by using HaluGen’s expanded psychedelics genetic testing panel
- The testing panel analyzes a series of relevant DNA biomarkers and utilizes pre-screening mental health surveys
- Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-therapeutics
- Entheon Biomedical Corp. was unchanged, trading at $0.07 at 12 PM ET
Ehave’s subsidiary KetaDASH has partnered with Entheon (ENBI) to improve patient outcomes.
KetaDASH will become one of the first psychedelic companies to use precision medicine to test patients by using HaluGen’s expanded psychedelics genetic testing panel.
The testing panel analyzes a series of relevant DNA biomarkers and utilizes pre-screening mental health surveys in order to provide insights into an individual’s risk and potential of adverse reactions with the use of ketamine.
By utilizing precision medicine, medical professionals will be able to test patients for genetic, personal and familial insights to better inform each patient’s psychedelic assisted therapy experience.
Genetics can play a key role in determining how an individual may respond to psychedelic-assisted psychotherapy.
“The benefit of the psychedelic profile is that it will enable the individuals and healthcare professionals at KetaDASH to personalize psychedelic therapy by providing an individual’s metabolic status for ketamine with their CYP2B6 genotype,” said Ben Kaplan, CEO of Ehave
“We are thrilled to support Ehave and KetaDASH with the use of our genetic test kits, and we believe that personalization will become an increasingly important feature of the psychedelic therapeutics landscape and applaud the pioneering steps that they are taking to deliver a standard of care that takes into account the individual nuance of every patient,” stated Timothy Ko, CEO of Entheon.
Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products for the purposes of treating addiction and substance use disorders.
HaluGen has developed a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, with the goal of improving patient care and reducing side effects and risk.
Entheon Biomedical Corp. was unchanged, trading at $0.07 at 12 PM ET.